Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination

Journal of Pathology

Volumn 201, Issue 2, 2003, Pages 319-327

  Kirk, John ^a   Plumb, Jonnie ^b   Mirakhur, Meenakshi ^b   McQuaid, Stephen ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

Blood brain barrier; Contrast enhancing lesions; Cytokines; Multiple sclerosis; Tight junctions; ZO 1

Indexed keywords

FIBRINOGEN;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; FEMALE; FROZEN SECTION; HEALTH CARE PLANNING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOFLUORESCENCE; MALE; MEMBRANE PERMEABILITY; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NORMAL HUMAN; PRIORITY JOURNAL; PROGNOSIS; TIGHT JUNCTION; WHITE MATTER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; CASE-CONTROL STUDIES; CEREBROVASCULAR CIRCULATION; FEMALE; FIBRINOGEN; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; STATISTICS, NONPARAMETRIC; TIGHT JUNCTIONS;

EID: 0141926694     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1434     Document Type: Article

References (44)

1. Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci 2001; 24: 719-725.
2. Fanning AS, Mitic LL, Anderson JM. Transmembrane proteins in the tight junction barrier. J Am Soc Nephrol 1999; 10: 1337-1345.
3. Tsukita S, Furuse M, Itoh M. Structural and signaling molecules come together at tight junctions. Curr Opin Cell Biol 1999; 11: 628-633.
4. Cserr HF, Knopf PM. Cervical lymphatics, the blood-brain barrier and immunoreactivity of the brain. In Immunology of the Nervous System, Keane RW, Hickey WF (eds). Oxford University Press: New York, 1997; 134-152.
5. Banks WA. Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. J Neurovirol 1999; 5: 538-555.
6. Tomkins O, Kaufer D, Korn A, et al. Frequent blood-brain barrier disruption in the human cerebral cortex. Cell Mol Neurobiol 2001; 21: 675-691.
7. Dallasta LM, Pisarov LA, Esplen JE, et al. Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. Am J Pathol 1999; 155: 1915-1927.
8. Brown H, Hien TT, Day N, et al. Evidence of blood-brain barrier dysfunction in human cerebral malaria. Neuropathol Appl Neurobiol 1999; 25: 331-340.
9. Boven LA, Middel J, Verhoef J, et al. Monocyte infiltration is highly associated with loss of the tight junction protein zonula occludens in HIV-1-associated dementia. Neuropathol Appl Neurobiol 2000; 26: 3356-3360.
10. Plumb J, McQuaid S, Mirakhur M, Kirk J. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol 2002; 12: 154-169.
11. Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis: implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115-121.
12. Wingerchuk DM, Lucchinetti CF, Noseworthy JH. Multiple sclerosis: current pathophysiological concepts. Lab Invest 2001; 81: 263-281.
13. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 1990; 113: 1477-1489.
14. Brown WJ. The capillaries in acute and subacute multiple sclerosis plaques: a morphometric analysis. Neurology 1978; 28: 84-92.
15. Harris JO, Frank JA, Patronas N, et al. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991; 29: 548-555.
16. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285.
17. Richert ND, Ostuni JL, Bash CN, et al. IFN beta 1b and methylprednisolone promote lesion recovery in MS. Mult Scler 2001; 7: 49-58.
18. Kuruganti PA, Hinojoza JR, Eaton MJ, et al. Interferon-beta counteracts inflammatory mediator-induced effects on brain endothelial cell tight junction molecules: implications for multiple sclerosis. J Neuropathol Exp Neurol 2002; 61: 710-724.
19. Gay FW, Drye TJ, Dick GWA, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification of the primary demyelinating lesion. Brain 1997; 120: 1461-1483.
20. Sanders V, Conrad AJ, Tourtellotte WW. On classification of post-mortem multiple sclerosis plaques for neuroscientists. J Neuroimmunol 1993; 46: 207-216.
21. van der Valk P, De Groot CJA. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol Appl Neurobiol 2000; 26: 2-10.
22. Daniel WW. Applied Nonparametric Statistics. Houghton-Miflin: Boston, 1978; 211-212.
23. Kwon EE, Prineas JW. Blood-brain barrier abnormalities in long standing multiple sclerosis lesions. An immunohistochemical study. J Neuropathol Exp Neurol 1994; 53: 625-636.
24. Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 2002; 200: 629-638.
25. Allen IV, McKeown SR. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 1979; 41: 81-91.
26. Goodkin DE, Rooney WD, Sloan R, et al. A serial study of new MS lesions and the white matter from which they arise. Neurology 1998; 51: 1689-1697.
27. Werring DJ, Brassat D, Droogan AG, et al. The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain 2000; 123: 1667-1676.
28. De Groot CJA, Bergers E, Kamphorst W, et al. Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. Brain 2001; 124: 1635-1645.
29. Filippi M, Rocca MA, Martino G, et al. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 1998; 43: 809-814.
30. Morita K, Sasaki H, Furuse M, Tsukita S. Endothelial claudin: claudin-5/TMVCF constitutes tight junction strands in endothelial cells. J Cell Biol 1999; 147: 185-194.
31. Akiguchi I, Tomimoto H, Suenaga T, et al. Blood-brain barrier dysfunction in Binswanger's disease; an immunohistochemical study. Acta Neuropathol (Berlin) 1998; 95: 78-84.
32. Luabeya MK, Dallasta LM, Achim CL, et al. Blood-brain barrier disruption in simian immunodeficiency virus encephalitis. Neuropathol Appl Neurobiol 2000; 26: 454-462.
33. Claudio L, Raine CS, Brosnan CF. Evidence of persistent blood-brain barrier abnormalities in chronic progressive multiple sclerosis. Acta Neuropathol (Berlin) 1995; 90: 228-238.
34. Hawkins CP, Munro MG, Landon DN, McDonald WI. Metabolically dependent blood-brain barrier breakdown in chronic relapsing experimental encephalomyelitis. Acta Neuropathol (Berlin) 1990; 83: 630-635.
35. Edens HA, Parkos CA. Modulation of epithelial and endothelial paracellular permeability by leukocytes. Adv Drug Deliv Rev 2000; 41: 315-328.
36. Walsh SV, Hopkins AM, Nusrat A. Modulation of tight junction structure and function by cytokines. Adv Drug Deliv Rev 2000; 41: 303-313.
37. Gay D, Esiri M. Blood-brain barrier damage in acute multiple sclerosis plaques. Brain 1991; 114: 557-572.
38. Woodroofe MN, Cuzner ML. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine 1993; 5: 583-588.
39. Blum MS, Toninelli E, Anderson JM, et al. Cytoskeletal rearrangement mediates human microvascular endothelial tight junction modulation by cytokines. Am J Physiol 1997; 273: H286-H294.
40. Cossins JA, Clements JM, Ford J, et al. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol (Berlin) 1997; 94: 590-598.
41. Rosenberg GA, Dencoff JE, Correa N, et al. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996; 46: 1626-1632.
42. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995; 37: 611-619.
43. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
44. Compston A. Future options for therapies to limit damage and enhance recovery. Semin Neurol 1998; 18: 405-414.